跳至主要内容
临床试验/NL-OMON51756
NL-OMON51756招募中2 期

Metabolic effects of ketohexokinase inhibition in individuals with non-alcoholic fatty liver disease - KHKi in NAFLD

niversiteit Maastricht0 个研究点目标入组 17 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
17

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • -Men and (postmenopausal) woman
  • -Age: >= 40 and <= 75 years
  • -BMI: 27-38 kg/m2
  • -Hepatic steatosis (i.e. IHL content >= 5.56%)
  • -Stable dietary habits (no weight loss or gain >3 kg in the 3 months prior to
  • -Participants are able to provide signed and dated written informed consent
  • prior to any study specific procedures

排除标准

  • -Type 2 diabetes
  • -Any contra-indication for MRI scanning
  • -Patients with congestive heart failure and and/or severe renal and/or liver
  • insufficiency
  • -Uncontrolled hypertension
  • -Alcohol consumption of >3 servings per day for man and >2 servings per day for
  • -Unstable body weight (weight loss or gain >3 kg in the 3 months prior to
  • -Engagement in structured exercise activities > 2 hours a week
  • -Previous enrolment in a clinical study with an investigational product during
  • the last 3 months or as judged by the Investigator which would possibly hamper
  • our study results
  • -Use of drugs that inhibit organic anion transporting polypeptide (OATP)
  • transporters (e.g. rifampicin, gemfibrozil, cyclosporine, erythromcyin and
  • clarithromycin)
  • -Subjects who do not want to be informed about unexpected medical findings

研究者

相似试验